Intellia Outlines Lonvo-z Launch Strategy Ahead of March 10, 2027 PDUFA
NTLA sits 33% above its 52-week low of $7.95.
Summary
Intellia's investor webcast laid out lonvo-z launch readiness: ~7,500 treatable U.S. HAE adults, 88% HCP prescribing intent, and pooled data showing 100% of patients off long-term prophylaxis, all ahead of the March 10, 2027 PDUFA date.
Key Events · Product Development and Regulatory · NTLA
-
Commercial Launch Case Detailed
Intellia sized the U.S. opportunity at about 7,500 treated HAE adults and noted that a single patient on long-term prophylaxis can cost the healthcare system more than $6 million per decade.
-
Strong Surveyed Prescriber Intent
Among 151 surveyed HCPs, 88% said they would prescribe lonvo-z to at least one patient and 65% within one year of approval; patient preference ran 2.8x that of the top-ranked clinical-stage LTP.
-
Pooled Data Show Durable Effect
Across 117 dosed patients with up to four years of follow-up, 100% were off long-term prophylaxis at the latest cutoff, and the 35-patient switch subset saw an 81% attack-rate reduction versus prior LTP.
-
PDUFA Date Set for March 10, 2027
The BLA is under Priority Review with a March 10, 2027 goal date; on September 3, 2026, the FDA stated it is not currently planning an advisory committee.
Analysis · NTLA · Life Sciences
Intellia used an investor webcast to shift the lonvo-z narrative from clinical data to commercial execution. The fresh figures center on market sizing and prescriber intent: roughly 7,500 treated U.S. HAE adults, a single patient on long-term prophylaxis costing the system more than $6 million per decade, and 88% of 151 surveyed HCPs saying they would prescribe lonvo-z to at least one patient, with 65% doing so within a year of approval. Pooled Phase 1/2/3 data now cover 117 dosed patients with up to four years of follow-up, showing 100% of patients off long-term prophylaxis at the latest cutoff and an 81% attack-rate reduction versus prior LTP in the 35-patient switch subset. None of this alters the regulatory timeline—the BLA is under Priority Review with a March 10, 2027 PDUFA date and no advisory committee planned—so the value lies in de-risking the launch curve rather than the approval itself. Whether investors accept Intellia's modeled 9-12 month access ramp and its pricing assumptions, which the presentation does not disclose, will drive the stock's reaction.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTLA was trading at $10.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $7.95 to $18.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.